GlassScriptPhysician profile
Henry T Tsai
NPI 1659572261
$10,031.85
in general payments reported to CMS, 2019-2025
27 companies · $200 in 2025
The $200 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,109 · 2020: $3,857 · 2021: $140 · 2022: $815 · 2023: $284 · 2024: $627 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,111.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $4,148.57 | 2019-2023 | Lynparza, Keytruda, Welireg |
| Array Biopharma INC | $3,887.34 | 2020-2024 | Braftovi, Lorbrena, Xalkori |
| Tempus Ai, INC | $418.33 | 2024-2025 | Xt Cdx |
| Janssen Biotech, INC. | $284.92 | 2019-2025 | Darzalex, Talvey, Imbruvica |
| Novartis Pharmaceuticals Corporation | $148.57 | 2022 | |
| Pfizer INC. | $126.51 | 2021-2023 | |
| Taiho Oncology, INC. | $113.98 | 2022-2023 | |
| Adaptive Biotechnologies Corporation | $101.05 | 2024 | Clonoseq |
| Bayer Healthcare Pharmaceuticals INC. | $93.63 | 2020-2021 | |
| Celgene Corporation | $87.74 | 2022-2023 | Reblozyl |
| Aveo Pharmaceuticals, INC. | $84.30 | 2025 | |
| Blueprint Medicines Corporation | $69.54 | 2020-2022 | |
| Eisai INC. | $64.55 | 2022 | |
| Menarini Silicon Biosystems, INC. | $64.28 | 2023 | Cellsearch |
| Alexion Pharmaceuticals, INC. | $62.64 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $54.18 | 2025 | Brukinsa |
| Glaxosmithkline, LLC. | $33.57 | 2022-2024 | Ojjaara |
| Pharmaessentia USA Corporation | $32.92 | 2023 | Besremi |
| Apellis Pharmaceuticals, INC. | $31.95 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $24.06 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $23.20 | 2022 | |
| Progenics Pharmaceuticals, INC. | $18.36 | 2022 | |
| Genentech USA, INC. | $17.26 | 2023 | Polivy, Gazyva |
| Foundation Medicine, INC. | $16.03 | 2022 | |
| Karyopharm Therapeutics INC. | $12.45 | 2020 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Tsai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.